# Amyloid PET imaging in Alzheimer's disease: A comparison of three radiotracers

**SM. Landau**[1,2], **BA. Thomas**[3], **L. Thurfjell**[4], **M. Schmidt**[5], **R. Margolin**[6], **M. Mintun**[7], **M. Pontecorvo**[7], **SL. Baker**[2], **WJ. Jagust**[1,2], and **the Alzheimer's Disease Neuroimaging Initiative**[*]

SM. Landau: slandau@berkeley.edu; BA. Thomas: Benjamin_Thomas@circ.a-star.edu.sg; L. Thurfjell: lennart.thurfjell@ge.com; M. Schmidt: mschmid4@its.jnj.com; R. Margolin: rmargoli@its.jnj.com; M. Mintun: mintun@avidrp.com; M. Pontecorvo: pontecorvo@avidrp.com; SL. Baker: slbaker@lbl.gov; WJ. Jagust: jagust@berkeley.edu

[1]Helen Wills Neuroscience Institute, University of California, Berkeley, CA

[2]Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA

[3]Institute of Nuclear Medicine, University College London, London, UK

[4]GE Healthcare, Uppsala, Sweden

[5]Janssen Pharmaceutica, NV, Bressen, Belgium

[6]Janssen Alzheimer Immunotherapy, South San Francisco, CA

[7]Avid Radiopharmaceuticals, Inc., Philadelphia, PA

## Abstract

**Purpose**—The increasing use of amyloid PET in Alzheimer's disease research and clinical trials has motivated efforts to standardize methodology. We compared tracer retention for ^{11}C radiotracer Pittsburgh Compound B (PiB) with two ^{18}F amyloid radiotracers (florbetapir and flutemetamol) using two study populations. We also examined the feasibility of converting between tracer-specific measures, using PiB as the common link between the two ^{18}F tracers.

**Methods**—One group of subjects (N=40) underwent PiB and flutemetamol imaging sessions and a separate group (N=32) underwent PiB and florbetapir imaging sessions. We compared cortical

and white matter retention for each F18 tracer relative to PiB, as well as several reference regions and image analysis methods. Associations between tracer pairs were used to convert thresholds for amyloid positivity between tracer-specific values.

**Results**—Cortical retention for each pair of tracers was strongly correlated regardless of reference region (flutemetamol-PiB, $\rho=0.84$–0.99; florbetapir-PiB, $\rho=0.83$–0.97) and analysis method ($\rho=0.90$–0.99). Compared to PiB, flutemetamol had higher white matter retention, while florbetapir had lower cortical retention. Two previously established independent thresholds for amyloid positivity were highly consistent when values were converted between tracer pairs.

**Conclusions**—Despite differing white and grey matter retention characteristics, cortical retention for each F18 tracer was highly correlated with PiB, enabling conversion of thresholds across tracer measurement scales with a high level of internal consistency. Standardization of analysis methods and measurement scales may facilitate the comparison of amyloid PET data obtained using different tracers.

## Keywords

---

Amyloid PET radiotracers are increasingly being used in Alzheimer's disease (AD) research and clinical trials of fibrillar amyloid-targeting treatments. The United States Food and Drug Administration (FDA) has approved the 18F radiotracers flutemetamol (Vizamyl) and florbetapir (Amyvid) for clinical use, and approval by the European Medicines Agency (EMA) has been established for florbetapir and is under review for flutemetamol.

The first amyloid PET imaging agent, the research tracer 11C Pittsburgh Compound B (PiB), has frequently been used to aid in validation of the more recently-developed 18F radiotracers [1–6]. Because each tracer has slightly different characteristics that influence quantification, the use of multiple tracers poses challenges for comparing results of studies using different tracers. It has also impeded the development of important measures such as thresholds for a significant amount of fibrillar brain amyloid deposition (amyloid positivity). For example, some reports suggest greater nonspecific white than grey matter retention in both F18 amyloid PET tracers [2, 3, 7] and in PiB [8, 9], a finding attributed to slower tracer clearance [10, 11]. This has led to uncertainty about white matter retention differences between tracers and their possible influence on cortical retention estimates [12]. Another potential source of variability is the use of different image processing pipelines that may involve heterogeneous spatial normalization techniques and/or strategies for defining reference regions and cortical regions of interest.

A worthwhile strategy for directly comparing two or more tracers is to examine data from a cohort scanned with both agents. Recent studies have used this strategy to examine associations between PiB and flutemetamol [2] and PiB and florbetapir [6, 4]. Here, we linked separate datasets from these studies (PiB-flutemetamol, PiB-florbetapir) and used the tracer in common (PiB) as a means to perform comparisons among the three tracers. To investigate the possibility that cortical retention and non-specific white matter retention differ between tracers, we investigated cortical grey matter and subcortical white matter

retention ratios for each F18 tracer relative to PiB. We also investigated the influence of different reference regions (brainstem/pons, cerebellar grey matter, whole cerebellum) on the cortical retention estimates for each pair of tracers. In addition, while our primary analysis used a common image processing pipeline, a secondary analysis investigated the influence of different image processing methods (calculating tracer retention in native space versus using a template-based transformation). Finally, we examined the feasibility of converting previously established tracer-specific thresholds amyloid positivity to other tracers. The reliable conversion of thresholds from one tracer to another is an important step for establishing greater methodological uniformity across amyloid PET studies.

It is important to note that our two study populations were not matched for amyloid status or other important subject and image acquisition characteristics, so we did not aim to compare tracer measurements between these study populations directly. Rather, we sought to examine characteristics of each F18 tracer relative to PiB for each study population separately, as a step towards developing standardization approaches.

## Materials and Methods

### Participants

Our study populations consisted of 40 participants (20 with mild cognitive impairment [MCI], 20 with AD) who underwent structural MRI and PET imaging sessions with PiB and flutemetamol within a <40 day time period at several centers in Europe as described previously [2]. The other sample consisted of 32 cognitively normal, MCI, and AD participants from the Alzheimer's Disease Neuroimaging Initiative (see below) who underwent structural MRI and PET imaging sessions with PiB and florbetapir with an approximately 1.5 years apart as described previously [6]. All participants gave written informed consent that was approved by the Internal Review Board of each participating institution.

### ADNI

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a longitudinal observational biomarker and clinical study supported by the NIH, private pharmaceutical companies, and nonprofit organizations. Approximately 50 medical center and university sites across the United States and Canada participate (http://adni.loni.usc.edu/about). The first ADNI protocol, ADNI1, enrolled approximately 800 participants (volunteers with normal cognition, mild cognitive impairment (MCI), and AD patients). Subjects underwent multiple longitudinal biomarker and cognitive measurements at 6–12 month intervals for 2–4 years. An add-on study enabled longitudinal PiB scanning in a subset of approximately 100 participants. Florbetapir scanning began with ADNI GO and has continued in ADNI 2, which is ongoing. While new subjects have been enrolled in ADNI GO/2, some ADNI1 subjects continued to participate. The ADNI participants included in the present study comprise a subset of 32 individuals who underwent at least one PiB scan and a subsequent florbetapir scan.

### Tracer synthesis and PET imaging

Tracer synthesis and image acquisition details are described in detail elsewhere for the PiB-flutemetamol population [13, 11, 2] and the PiB-florbetapir population [6], http://adni-info.org. Briefly, for the PiB-flutemetamol study, PiB images ($6 \times 5$min frames acquired from 40–70 min post-injection) and flutemetamol images ($6 \times 5$min frames acquired at 85–115 min post-injection) were realigned and smoothed to a common resolution of 6mm FWHM to account for variations in data acquisition across scanners. For the ADNI PiB-florbetapir cohort, PiB and florbetapir images ($4 \times 5$min frames acquired at 50–70 min post-injection) were realigned and smoothed to a common resolution of 8mm FWHM.

### Cortical retention ratio quantification

Subsequent image processing with Freesurfer proceeded in parallel for our two datasets. Structural T1 images acquired concurrently with the PET images were used as a structural template to define cortical regions of interest and reference regions in native space for each subject using Freesurfer (version 4.5.0; surfer.nmr.mgh.harvard.edu) as described previously [6, 14, 15].

PET scans were coregistered to the structural MR scans, which were segmented and parcellated into individual cortical regions with Freesurfer. They were subsequently used to extract mean PiB, flutemetamol, and florbetapir cortical retention ratios from gray matter within lateral and medial frontal, anterior and posterior cingulate, lateral parietal, and lateral temporal cortices. Retention in four large regions of interest (frontal, cingulate, parietal, and temporal cortices) was averaged to create a single cortical composite region. Finally, mean retention in brainstem, cerebellar grey matter, and whole cerebellum (grey and white matter) reference regions was computed. Retention ratios were generated by dividing each of the five cortical regions of interest (frontal, cingulate, parietal, temporal, and cortical composite) by each of the three reference regions (brainstem/pons, cerebellar grey matter, whole cerebellum), resulting in 15 retention ratios for each subject per tracer. We also examined retention in a Freesurfer-defined subcortical white matter region relative to cerebellar grey matter.

### Comparison of image analysis methods

The Freesurfer method analyzes the data in native space. To investigate whether a standard space method that does not rely on structural images would generate similar results, we processed all scans with a fully automated PET-only adaptive template method that has been described recently [16]. Briefly, this method involves spatial normalization of PET images to an amyloid PET adaptive template in Montreal Neurological Institute (MNI) space that is generated using flutemetamol scans and can accommodate scans ranging from low to high tracer cortical retention. The adaptive template fitting method proceeds by iteratively optimizing the template appearance and spatial transformation to converge on an optimal set of parameters for a particular subject's scan. Each pair of F18 and PiB images were co-registered to one another, and the adaptive template method was used to spatially normalize the PIB scan to MNI template space. Normalization of the PiB scan (rather than F18 tracer scan) to the template made it possible to avoid bias since the template is based on flutemetamol images. The subject-specific transformation was then used to transform each

co-registered F18 scan to MNI template space. Retention ratios were computed for a cortical composite and reference regions (pons, cerebellar grey matter and whole cerebellum) that are analogous to the native-space versions used with the Freesurfer method, except that Freesurfer generates a brainstem region including the pons and adjacent structures while the adaptive template method generates a smaller pons-only segment of the brainstem.

### Statistical analyses

Wilcoxon signed-rank tests were used to compare mean white matter retention for each pair of tracers (PiB and flutemetamol, PiB and florbetapir), and $\alpha=0.05$ was Bonferroni-corrected to adjust for the 4 comparisons per tracer pair, resulting in $\alpha=0.012$. Correlations between cortical retention for each pair of tracers and for image processing methods were assessed using Spearman's rho ($\rho$) because the datasets were not normally distributed. Slope and intercept values from the linear regression equations representing associations between pairs of tracers were used to convert threshold values between radiotracer units.

## Results

### Study populations

While we did not perform direct comparisons between our unmatched study populations because they were unmatched in several ways, demographic information is summarized for the two study populations (Table 1). The PiB-florbetapir population (the ADNI participants) were slightly older, had a higher proportion of men, and had a slightly higher education level compared with the PiB-flutemetamol subjects. The primary difference, however, between the two populations was that due to study design features, the pair of PET scans was concurrent for the PiB-flutemetamol population (<40 days between sessions) whereas the PiB-florbetapir scans were separated by an average of 1.5 (+/−0.7) yrs. Because of this longer time interval, the diagnosis of 7/32 subjects (22%) changed between their initial (PiB) scan and their subsequent (florbetapir) scan (see Table 1 legend for details).

### Subcortical white matter retention

The pattern of subcortical white matter retention relative to cerebellar grey matter differed for each F18 tracer relative to PiB (Table 2, Figure 1). In the PiB-flutemetamol group (Figure 1A), white matter retention was higher in flutemetamol (2.03+/−0.26) compared to PiB (1.81+/−0.27) (p<0.001). White matter retention in the PiB-florbetapir group (Figure 1B) did not meet our corrected statistical threshold (see Methods) but was marginally higher (p=0.04) for PiB (1.87+/−0.29) compared to florbetapir (1.77+/−0.27).

### Cortical retention

In the PiB-flutemetamol group, cortical retention for PiB was higher than flutemetamol using brainstem and whole cerebellum normalization (p 0.001), but there was no difference in PiB and flutemetamol cortical retention with cerebellar grey matter normalization. In the PiB-florbetapir group, cortical retention was consistently higher for PiB compared to florbetapir across all reference regions (p 0.01) (Table 2, Figure 1).

Composite cortical retention associations for the PiB-flutemetamol and PiB-florbetapir groups are plotted for all three reference regions (Figure 2). Spearman's rho correlations and slopes representing the linear regression for each tracer pair across cortical regions of interest (frontal, cingulate, parietal, temporal, and composite summary region) and with all three reference regions (brainstem, cerebellar grey matter, whole cerebellum) also appear in the supplementary table. The range of slopes for PiB-florbetapir associations was similar across all cortical regions of interest and reference regions (slope = 0.59 – 0.66), indicating a narrower range of cortical retention values for florbetapir compared to PiB. For PiB-flutemetamol associations, on the other hand, slopes were closer to unity for cerebellar grey matter-normalized (slope = 0.79 – 0.83) and whole cerebellum-normalized values (slope = 0.72 – 0.79), indicating that cortical retention is similar for PiB and flutemetamol when cerebellar reference regions are used.

Associations between each pair of tracers was high ($p < 0.001$ in all cases) across all individual cortical regions examined, and no cortical region consistently showed the highest or lowest correlation. Associations were highest with brainstem normalization (PiB-flutemetamol, ρ range across cortical regions of interest = 0.98 – 0.99; PiB-florbetapir, ρ = 0.95 – 0.97), compared to associations with cerebellar grey matter normalization (PiB-flutemetamol, ρ = 0.84 – 0.93; PiB-florbetapir, ρ = 0.83 – 0.86) and whole cerebellum normalization (PiB-flutemetamol, ρ = 0.88 – 0.95; PiB-florbetapir, ρ = 0.86 – 0.90). However, brainstem normalization also resulted in the lowest slopes overall (PiB-flutemetamol, slope = 0.64 – 0.67; PiB-florbetapir, slope = 0.61 – 0.66), indicating a reduced range of flutemetamol and florbetapir cortical retention relative to PiB.

### Image processing methods

Comparing associations between Freesurfer and adaptive template processing indicated that cortical composite averages were highly correlated within each tracer. Associations between composite values measured using the Freesurfer (native space) processing method and the adaptive template method ranged from 0.90 to 0.99, and were highest for the brainstem-normalized data (Table 3). In addition, associations between image processing methods were comparable across tracers (Figure 3).

### Conversion of thresholds between radiotracers

Using the Freesurfer-based datasets, we used the linear association between pairs of composite retention ratios to convert amyloid positivity threshold values from those established for one tracer to corresponding values for another, as we have shown previously for florbetapir and PiB [6]. This method enables direct comparison of independently-derived thresholds, using PiB as the common tracer linking the F18 tracers. Specifically, we used composite summary measures from our PiB-flutemetamol and PiB-florbetapir datasets to calculate linear regression equations representing the association between pairs of tracers (analyzed either with the same or with different reference regions). These regression equations were then used to convert threshold values from one tracer to another.

Using this strategy, we examined the feasibility of converting a previously-validated PiB value of 1.47 (based on cerebellar grey matter normalization), which was originally derived

from a receiver operating characteristic (ROC) analysis of AD and cognitively normal ADNI participants [17]. This PiB threshold was transformed to florbetapir (1.13) and flutemetamol (1.21) values, both with whole cerebellum normalization (Figure 4A). Next, we examined a previously-validated florbetapir threshold, which was derived from the upper bound of the 95% confidence interval above the mean uptake in a population of young, cognitively normal individuals [18] and further validated by histopathology data in a separate population [19]. This threshold was subsequently converted to a value compatible with the Freesurfer processing stream [20], resulting in a value of 1.11 (based on whole cerebellum normalization). This was converted to a value of 1.27 for PiB (whole cerebellum normalization), which was in turn converted to a value of 1.20 for flutemetamol (whole cerebellum normalization) (Figure 4B). Using this approach, we can derive comparative thresholds between florbetapir and flutemetamol of 1.11 and 1.20, respectively, despite the fact that these two tracers were not directly compared in the same subjects.

## Discussion

We compared amyloid PET measurements for two different study samples, one that received both PiB and flutemetamol scans, and another that received PiB and florbetapir scans. To our knowledge, flutemetamol and florbetapir have not yet been compared to one another previously. Overall, PiB-florbetapir and PiB-flutemetamol correlations were high. Using a common image processing pipeline for both datasets, and using PiB as the link between the two datasets, we compared PiB-flutemetamol and PiB-florbetapir associations and used them to examine the reproducibility of two independently-derived thresholds for amyloid positivity.

We converted these two cutoff thresholds (a PiB value of 1.47 and a florbetapir value of 1.11) into flutemetamol units using linear regression equations, which resulted in almost identical values of 1.20 and 1.21 (Figure 4A (right) and 4B (right)). Similarly, conversion of the 1.47 PiB threshold to florbetapir values resulted in a value of 1.13 which was extremely similar to the autopsy-validated florbetapir cutoff of 1.11. The fact that these cut-offs were derived from independent populations, tracers, and criteria, yet were internally consistent when converting between tracer units indicates strong reliability of the linear association between tracers despite the use of relatively small and unmatched populations (PiB-flutemetamol group, N=40; PiB-florbetapir group, N=32) to define these relationships.

Selection of cutoffs that are consistent across studies and tracers is increasingly important as amyloid PET imaging becomes more widely used. We see the current study as a proof of concept of the general approach for comparing amyloid PET tracers on the same scale (e.g. 0–100) and there are currently efforts underway to formalize this approach (with units called "centiloids"). Ideally, a tracer-specific cutoff should be compared to a population of young normal control subjects. Since this is not possible for every study, the method proposed here is an alternative that enables conversion of thresholds between tracers and reference regions with reasonable consistency. Nonetheless, selection of a cutoff selection should depend on the goals of the trial or study, since a more liberal or more conservative threshold will have different consequences depending on the clinical population, research question, or clinical trial it is applied to.

We also examined differences between the tracer pairs in cortical and white matter retention. Cortical retention was higher for PiB than florbetapir regardless of reference region; similarly, it was higher for PiB than flutemetamol in 2 out of 3 reference regions. There was substantial white matter retention for all three tracers, but the pattern was different for each F18 tracer relative to PiB. Specifically, white matter retention was higher for flutemetamol compared to PiB (Figure 1, Table 2). On the other hand, white matter retention was comparable between florbetapir and PIB; in fact, it was marginally higher for PiB than florbetapir, although the difference didn't meet our corrected statistical threshold.

White matter retention introduces a number of challenges in making accurate cortical measurements and comparing tracers. For example, the difference in white matter retention between tracers influences measurement of cortical retention when using a reference region with white matter content. When normalizing cortical values by brainstem (the reference region with the highest proportion of white matter) the relatively higher white matter retention in flutemetamol compared to florbetepir reduces the cortical retention ratios more for flutemetamol, resulting in nearly identical slopes for PiB-flutemetamol and PiB-florbetapir. Another important concern is the influence of white matter by grey matter and vice versa due to partial volume effects. The high white matter retention we observed for PiB may be due to the influence of relatively higher PiB grey matter retention on neighboring white matter voxels. This possibility is consistent with a recent report that high cortical flutemetamol retention results in higher estimated white matter retention for the same reason [12]. While the partial volume effect would be expected to influence the PiB-flutemetamol dataset as well, the fact that we did not observe this may be due to a disproportionate amount of non-specific retention for flutemetamol. In other words, the effect of flutemetamol's high white matter retention may have exceeded the partial volume effect of high cortical PiB on PiB white matter.

A comparison of different image processing methods indicated high concordance between cortical retention ratios generated via the Freesurfer method, which relies on a co-registered structural MRI image and quantifies tracer retention in the subject's native space, and the adaptive template method, which relies on warping amyloid PET data to a template without use of a structural image. There was strong agreement between these image processing methods across pairs of tracers and reference regions, suggesting that amyloid PET measurements are robust against image warping and different methods for defining cortical and reference regions. These findings are consistent with our previous comparison of PiB and florbetapir using the Freesurfer-based method and a different PET template approach [6]. However, the actual threshold level may vary depending on how target and reference regions are defined. The use of the entire brainstem (Freesurfer) versus a pons-only region (adaptive template) did produce substantially different results since correlations between processing methods were highest for this reference region as a whole (Supplementary table).

The correlation and slope measurements derived from the PiB-flutemetamol and PiB-florbetapir associations provide complementary information. The correlation indicates how precisely the retention for an individual scanned using one tracer can be estimated given another tracer's retention. We found that correlations between each pair of radiotracers were highest with brainstem normalization and lower with cerebellar grey matter or whole

cerebellum normalization (Figure 2, supplementary table). One possible explanation is that use of the brainstem reduces white matter retention variability between tracers and between individuals that is independent of the level of cortical retention (since brainstem white matter retention, unlike subcortical white matter retention, is not influenced by partial volume effects on cortical retention).

The magnitude of the slope, on the other hand, indicates the degree of similarity between the range of cortical retention values for one tracer relative to another. We observed that florbetapir cortical retention was lower compared to PiB across all reference regions (slope = 0.61 to 0.65), whereas for PiB-flutemetamol associations, the slope varied; it was lowest for brainstem-normalized data (Figure 1; 0.65) and higher for whole cerebellum- and cerebellar grey matter- (0.72 and 0.81, respectively; Figure 1) normalized data. When normalizing cortical values by brainstem (the reference region with the highest proportion of white matter) the relatively higher white matter retention for flutemetamol compared to florbetepir reduces the cortical retention ratios more for flutemetamol, resulting in nearly identical slopes for PiB-flutemetamol and PiB-florbetapir.

This study has a number of limitations which were primarily related to the combination of study designs and populations. While we have focused on variability between tracer associations due to characteristics of the tracers themselves (e.g. differences in non-specific uptake), there are a number of possible sources of variability in tracer pair associations such as differing proportions of subjects with high versus low amyloid in our two populations. Slightly lower correlations for the PiB-florbetapir group compared to the PiB-flutemetamol group may also be due to the longer time interval between scanning sessions. This longer PiB-florbetapir time interval also meant that about a fifth of subjects experienced a change in diagnosis between scanning sessions. However, we previously reported that subjects who experienced a change in diagnostic status did not appear to show a greater discrepancy between PiB and florbetapir cortical retention compared with those whose diagnosis remained stable [6]. The two populations also differed with respect to smoothing and the time window used to calculate tracer retention ratios. The PiB-florbetapir scans were smoothed to an $8\times8\times8mm^3$ resolution while the PiB-flutemetamol scans were smoothed to a $6\times6\times6mm^3$ resolution, so partial volume effects were slightly greater for the PiB-florbetapir group. However, it is unclear whether this may have influenced the group differences we observed since the group differences were likely due to a combination of partial volume effects and tracer characteristics. For the PiB-flutemetamol group, PiB images were acquired at 40–70 min post-injection and flutemetamol images were acquired at 85–115 min; whereas for the PiB-florbetapir group, both PiB and florbetapir were acquired at 50–70 min. These differing time windows could have influenced the relative cortical and white matter effects we observed if, for example, white to grey matter retention increases over time. Finally, test-retest error accounts for some of the between-tracer variability we observed. Previous studies have reported test-retest error estimates in cortical retention associated with repeated amyloid PET scans on the same individuals from 1% to 9% [18, 21, 2].

To summarize, we found that despite differing cortical and white matter retention characteristics, amyloid PET imaging tracers can be compared to one another using cohorts scanned with multiple tracers and processed using a common image analysis pipeline.

Thresholds for categorizing subjects as amyloid positive or negative can be converted between tracers with a high level of consistency. The use of cohorts scanned with more than one tracer, including a common tracer such as PiB, enables flexible comparison of thresholds using linear relationships representing relationships between cortical retention ratios. The availability of validated cross-tracer thresholds will benefit the use of amyloid PET in clinical research, including trials of potential therapeutics.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

## References

1. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008; 7(2):129–35.10.1016/S1474-4422(08)70001-2 [PubMed: 18191617]

2. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010; 68(3):319–29.10.1002/ana.22068 [PubMed: 20687209]

3. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. European journal of nuclear medicine and molecular imaging. 2012; 39(6):983–9.10.1007/s00259-012-2088-x [PubMed: 22398958]

4. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 201210.1136/jnnp-2012-302548

5. Cselenyi Z, Jonhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med. 2012; 53(3):415–24.10.2967/jnumed.111.094029 [PubMed: 22323782]

6. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med. 2013; 54(1):70–7.10.2967/jnumed.112.109009 [PubMed: 23166389]

7. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010; 51(6):913–20.10.2967/jnumed.109.069088 [PubMed: 20501908]

8. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008; 29(10): 1456–65.10.1016/j.neurobiolaging.2007.03.029 [PubMed: 17499392]

9. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007; 68(20):1718–25. 68/20/1718 [pii]. 10.1212/01.wnl. 0000261919.22630.ea [PubMed: 17502554]

10. Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009; 50(2):198–204.10.2967/jnumed.108.057984 [PubMed: 19164220]

11. Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009; 50(8):1251–9.10.2967/jnumed.109.063305 [PubMed: 19617318]

12. Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. European journal of nuclear medicine and molecular imaging. 2011; 38(6):1104–19.10.1007/s00259-011-1745-9 [PubMed: 21336694]

13. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55(3):306–19.10.1002/ana.20009 [PubMed: 14991808]

14. Landau SM, Marks SM, Mormino EC, Rabinovici GD, Oh H, O'Neil JP, et al. Association of lifetime cognitive engagement and low beta-amyloid deposition. Arch Neurol. 2012; 69(5):623–29.10.1001/archneurol.2011.2748 [PubMed: 22271235]

15. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009; 132(Pt 5):1310–23. awn320 [pii]. 10.1093/brain/awn320 [PubMed: 19042931]

16. Lundqvist R, Lilja J, Thomas BA, Lotjonen J, Villemagne VL, Rowe CC, et al. Implementation and Validation of an Adaptive Template Registration Method for 18F-Flutemetamol Imaging Data. J Nucl Med. 201310.2967/jnumed.112.115006

17. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009; 73(15):1193–9. 73/15/1193 [pii]. 10.1212/WNL.0b013e3181bc010c [PubMed: 19822868]

18. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012; 53(3):378–84.10.2967/jnumed.111.090340 [PubMed: 22331215]

19. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012; 11(8):669–78.10.1016/S1474-4422(12)70142-4 [PubMed: 22749065]

20. Landau SM, Mintun M, Joshi A, Koeppe RA, Petersen RC, Aisen P, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 201210.1002/ana.23650

21. Tolboom N, Yaqub M, Boellaard R, Luurtsema G, Windhorst AD, Scheltens P, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. European journal of nuclear medicine and molecular imaging. 2009; 36(10):1629–38.10.1007/s00259-009-1129-6 [PubMed: 19384547]

**Figure 1.**
Bar plots comparing retention for each tracer in subcortical white matter and the cortical composite region relative to brainstem/pons, cerebellar grey matter, and whole cerebellum are shown for (A) the flutemetamol-PiB group and (B) the florbetapir-PiB group. Asterisks represent significant differences for each pair of regional associations.

**Figure 2.**
Associations between summary cortical composite retention ratios are plotted for (A) subjects who received flutemetamol and PiB scans and (B) subjects who received florbetapir and PiB scans. Three reference regions (left, brainstem/pons; middle, cerebellar grey matter; and right, whole cerebellum) were used. Linear regression equations and Spearman's rho correlations are given for each association.

**Normalized by brainstem/pons**  **Normalized by whole cerebellum**

A. Flutemetamol

$y = 0.79x + 0.01$
$\rho = 0.96$

$y = 1.04x + 0.07$
$\rho = 0.93$

B. Florbetapir

$y = 0.87x - 0.01$
$\rho = 0.97$

$y = 1.04x + 0.02$
$\rho = 0.94$

**Figure 3.**
Example associations between the two image processing methods are shown (see complete list of associations across tracers and reference regions in Table 3). Linear regression equations and Spearman's rho correlations are shown representing associations between the Freesurfer-based and adaptive template-based cortical composite values for A) flutemetamol and B) florbetapir, each with brainstem/pons and whole cerebellum normalization.

**A.**

**PiB-based cereb GM cutoff (1.47) converted to florbetapir wh cereb units (1.13)**

$y = 0.54x + 0.34$

**PiB-based cereb GM cutoff (1.47) converted to flutemetamol wh cereb units (1.21)**

$y = 0.68x + 0.21$

**B.**

**Florbetapir-based wh cereb cutoff (1.11) converted to PiB wh cereb units (1.27)**

$y = 1.39x - 0.27$

**Florbetapir-based PiB wh cereb (1.27) cutoff converted to flutemetamol wh cereb units (1.20)**

$y = 0.72x + 0.29$



**Figure 4.**
Two previously established thresholds for cortical amyloid positivity can be converted between radiotracers using PiB as the link between flutemetamol and florbetapir. For example (A), a PiB-based threshold of 1.47 was converted to florbetapir and flutemetamol units, each linear regression equation to convert 1.47 (PiB units, cerebellar grey matter normalization) to 1.13 (florbetapir units, whole cerebellum normalization) and to 1.20 (flutemetamol units, whole cerebellum normalization). In a second example (B), a florbetapir-based threshold of 1.11 (whole cerebellum normalized) was converted to PiB units (1.27, whole cerebellum normalization), and this new PIB threshold was in turn converted to flutemetamol units, resulting in a value value (1.20, whole cerebellum) that is

almost identical to the flutemetamol threshold calculated from the first threshold (A, flutemetamol threshold 1.21).

**Table 1**

| | N (by diagnostic group) | Age, yrs (SD) | Time between PiB and F18 scans (yrs) | Sex, % female | Education, yrs (SD) | ApoE4 carriers |
|---|---|---|---|---|---|---|
| **PiB - flutemetamol group** | 40 (20 MCI, 20 AD) | 70.7 (7.1) | < 0.1 | 60% | 14.9 (3.5) | na |
| **PiB - florbetapir group** | 32 (6 N, 22 MCI, 4 AD) * | 75.7 (6.6) | 1.5 (0.7) | 31% | 16.1 (3.0) | 53% |

*
Diagnosis at the time of PiB scan is shown.

Between PiB and florbetapir scans, 1 Normal converted to MCI, 1 MCI reverted to Normal, and 5 MCIs converted to AD

**Table 2**

| | | Subcortical WM | | Composite retention ratio | | |
| --- | --- | --- | --- | --- | --- | --- |
| | | normalized by cerebellar GM | normalized by brainstem | normalized by cerebellar GM | normalized by whole cerebellum |
| **Flutemetamol - PiB group** | **flutemetamol** | mean (SD) | 2.03 (0.26) | 0.85 (0.23) | 1.70 (0.42) | 1.39 (0.35) |
| | | range | 1.58 – 2.54 | 0.48 – 1.28 | 1.06 – 2.46 | 0.83 – 2.05 |
| | **PiB** | mean (SD) | 1.81 (0.27) | 1.12 (0.35) | 1.74 (0.48) | 1.53 (0.46) |
| | | range | 1.30 – 2.37 | 0.57 – 1.77 | 1.01 – 2.72 | 0.43 – 2.34 |
| **Florbetapir - PiB group** | **florbetapir** | mean (SD) | 1.77 (0.27) | 0.88 (0.21) | 1.38 (0.32) | 1.22 (0.28) |
| | | range | 1.21 – 2.48 | 0.64 – 1.56 | 0.93 – 2.26 | 0.87 – 2.01 |
| | **PiB** | mean (SD) | 1.87 (0.29) | 0.95 (0.31) | 1.63 (0.47) | 1.42 (0.42) |
| | | range | 1.39 – 2.41 | 0.57 – 1.58 | 1.06 – 2.39 | 0.91 – 2.16 |

Regions in which a significant difference was observed between tracer pairs are highlighted in grey.

**Table 3**

|  |  | Composite/Brainstem-pons | Composite/Cereb GM | Composite/Whole cereb |
|---|---|---|---|---|
| PiB - flutemetamol | ρ (PiB) | 0.96 | 0.90 | 0.93 |
|  | ρ (flutemetamol) | 0.98 | 0.92 | 0.95 |
| PiB - florbetapir | ρ (PiB) | 0.97 | 0.94 | 0.94 |
|  | ρ (florbetapir) | 0.99 | 0.97 | 0.97 |

All correlations are significant at p < 0.001